CF Foundation’s Drug Discovery Investment Leads Galapagos to Pursue CF Drug Development
| 1 min read

A Belgium biotech company called Galapagos announced it will pursue cystic fibrosis drug development, following a successful collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), an affiliate of the Cystic Fibrosis Foundation.

CFFT invested $3.2 million in a drug discovery program with Galapagos to discover drug targets that could potentially lead to successful therapies. The program resulted in the identification of 19 targets, setting the stage for drug development.

“We are pleased that Galapagos has joined the effort to find effective therapies to fight cystic fibrosis,” said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. “This is another success for the Foundation's Therapeutics Development Program and furthers our mission of developing new drugs for the CF community.”

Read the Galapagos release.

Share this article
Topics
Research
Recent news
Teens Advocate for the PASTEUR Act as Part of the CF Foundation’s 14th Annual Teen Advocacy Day
News | 4 min read
CF Foundation Awards $1.6 Million to Improve Detection of Lung Transplant Complication
News | 5 min read
CF Foundation Announces New National Advocacy Chairs
News | 5 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe